Radiopharm Theranostics shares rise after interim Phase 2b data showed 92% MRI concordance for RAD 101 imaging in brain metastases.
Cencora agrees to buy a majority stake in OneOncology for about $5 billion, pauses buybacks, and reiterates fiscal 2026 sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback